WALTHAM, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of
high-value products to improve the process of manufacturing biologic drugs, today announced that it will participate in Stephens’
Fall Investment Conference, being held November 8-9, 2016 in New York. Repligen President and CEO Tony J. Hunt, and CFO Jon
Snodgres, will deliver a roundtable presentation on Tuesday, November 8 at 11:00 a.m.
Repligen’s current investor presentation is accessible through the Investor Events section of the Company’s website.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of
highly innovative products used to manufacture biologic drugs. Our bioprocessing products are sold to major life sciences
companies, biopharmaceutical development companies and contract manufacturing organizations worldwide. We are the leading
manufacturer of Protein A affinity ligands, a critical component of Protein A resins that are used to separate and purify
monoclonal antibody-based therapeutics. In upstream processes, our XCell™ ATF systems and growth factors are used to accelerate and
increase productivity during the cell culture stage of biologic drug manufacturing. In downstream processes, we developed and
market our innovative line of OPUS® chromatography columns that we deliver pre-packed with our customers’ choice of
resin for their bench-scale through clinical production-scale purification needs. Repligen’s corporate headquarters are in Waltham,
MA (USA) and our manufacturing facilities are located in Waltham, MA, Lund, Sweden and Weingarten, Germany.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are
cautioned that statements in this press release which are not strictly historical statements including, without limitation,
statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions,
constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that
could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings
with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements,
except as required by law.
Contact: Sondra S. Newman Senior Director Investor Relations Repligen Corporation (781) 419-1881 snewman@repligen.com
